Special Issue

Development of Vaccines Against Bacterial Infections

Message from the Guest Editors

The Special Issue aims at providing a comprehensive overview of the current state of research in the field of vaccine development against bacterial infections. Bacterial infections continue to pose significant challenges to public health worldwide. This Special Issue will cover a wide range of topics related to bacterial vaccine development, including advances in vaccine design, mechanisms of bacterial pathogenesis, the preclinical and clinical evaluation of vaccine candidates, the use of bacteria in vaccine development, and strategies for vaccine delivery and formulation. Contributions from leading researchers and experts in the field will provide insights into the latest scientific advancements, challenges, and opportunities in the development of vaccines against bacterial infections. The goal of this Special Issue is to foster collaboration and knowledge exchange among scientists, clinicians, policymakers, and industry stakeholders to accelerate the development of effective vaccines that can mitigate the burden of bacterial diseases and improve global health outcomes.

Guest Editors

Prof. Dr. John Hwa Lee

Department of Veterinary Medicine, Jeonbuk National University, Jeonju, Republic of Korea

Prof. Dr. Amal Senevirathne

College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea

Deadline for manuscript submissions

30 September 2025



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/201202

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

